Denosumab: A Review in Postmenopausal Osteoporosis

Area of Science:

• Endocrinology
• Rheumatology
• Pharmacology

Background:

• Denosumab is a monoclonal antibody targeting RANKL, a key mediator of bone resorption.
• It is approved for treating postmenopausal osteoporosis in women at high fracture risk or with intolerance to other therapies.

Purpose of the Study:

• To review the efficacy and safety of denosumab in postmenopausal women with osteoporosis.
• To assess its long-term benefits and risks, including fracture reduction and bone mineral density changes.

Main Methods:

• Analysis of data from phase 3/4 studies, including the FREEDOM trial and its open-label extension.
• Comparison of denosumab's effects on fractures and bone mineral density (BMD) versus placebo and bisphosphonates.

Main Results:

• Denosumab significantly reduced vertebral, nonvertebral, and hip fractures, and increased BMD over up to 10 years.
• It demonstrated greater BMD improvement than bisphosphonates, though anti-fracture efficacy differences remain unclear.
• Generally well-tolerated, but an increased risk of multiple vertebral fractures was noted post-discontinuation.

Conclusions:

• Denosumab is a crucial treatment for postmenopausal osteoporosis, offering sustained fracture protection and BMD improvement.
• The risk of rebound vertebral fractures after discontinuation requires careful consideration of follow-up management strategies.